FIGURE INDEX

Fig.No.	Figure Title	Page
1.	Percentage of viable lymphocytes	40
2	Percentage of viable Ehlrich ascitic carcinoma cells	41
3	Percentage of B and T lymphocytes from spleen of mice	43
4	No. of plaque forming cells from spleen of mice treated with ETE in Primary and Secondary immune response	43
5	Haemagglutination (Ab) titre in Primary response	44
6	Haemagglutination (Ab) titre in secondary immune response	45
7	Estimation of serum IgG level (pgm/ml) by ELISA in secondary immune response with ETE treatment, alcohol (control) and no treatment	46
8	Blastogenic responses of lymphocytes from spleen treated with ETE, alcohol and ConA	46
9	Blastogenic responses of lymphocytes from lymph node treated with ETE, alcohol and ConA.	47
10	Pattern of incorporation of ^{3}H-thymidine by lymphocytes treated for different hours with ETE	48
11	The level of incorporation of ^{3}H-thymidine by lymphocytes treated for different hours with different doses (in µl) of ETE.	49

12	DNA histograms by FACS for cell cycle analysis of splenic lymphocytes	50
13	DNA histograms by FACS for cell cycle analysis of ascitic fibrosarcoma cells	52
14	DNA histograms by FACS for cell cycle analysis of Ehlrich ascitic carcinoma cells.	53
15	Scanning electron micrographs of murine lymphocytes after 16 hrs	54
16.	SEM images of murine lymphocytes from spleen after 24 hrs	55
17	Scanning electron micrographs of Ehlrich ascitic carcinoma cells	56-57
18	SEM images of Ehlrich ascitic carcinoma cells after 24 hrs	57
19	Transmission electron microscopic images of splenic lymphocytes after 24 hrs	58
20	TEM of Ehlrich ascitic carcinoma cells	59-60
21	Phase contrast micrograph of typical conjugate	61
22	Percentage of conjugate formed between tumor target cells and lymphocytes	61
23	Percentage of tumor cells with blebbings and subsequent death after conjugate formation	62

24	Photomicrographs of Ehlrich ascitic carcinoma cells stained with Giemsa	62
25	Percentage of cytotoxic response mounted by ETE treated lymphocytes	63
26	Percentage of cytotoxicity towards tumor cells after 6 hrs of *in vitro* ETE treatment	64
27	Rate of solid tumor growth (in cm^2) -schedule I	65
28	Rate of solid tumor growth in mice administered ETE orally	66-67
29	Least square fit analysis of solid tumor growth	67-69
30	Rate of ascitic tumor growth with ETE, administered intravenously twice prior to the induction of tumor	69-70
31	Change in paw size of DTH mice with ETE and curcumin	71
32	Photograph showing the DTH reaction of paw	72
33	Percentage of different leukocytes at the inflammation site	73
34	Photomicrograph of different leukocytes at the inflammation site	74-75
35	Phase contrast image of $CD4^+$ T cells isolated mice with MACS	75
36	Total count of lymphocytes and $CD4^+$ T cells	76
37	Inhibition of serum TNF- α level in pgm/ml quantity, judged by ELISA	77

38	Inhibition of superoxide and hydroxyl ion generation	78
39	Copper ascorbate induced H_2O_2 generation in lymphocytes and tumor cells	78
40	L- arginine derived NO production in both lymphocytes as well as tumor cells	79
41	TLC strip showing bands	80
42	Variations in the color of ETE, F1, F2 & Curcumin in the ethanol solutions.	81
43	Percentage of B and T lymphocytes	84
44	No. of plaque forming cells (PFCs) from spleen of mice treated with ETE, F1, F2, Curcumin (10 to 100μM), alcohol and no treatment in	85
45	Haemagglutination (Ab) titre with antiserum from mice injected with SRBCs	86
46	Haemagglutination (Ab) titre of secondary immune response	87
47	Estimation of serum IgG level (pgm/ml) by ELISA.	89